Prokidney Corp (PROK) Stock Analysis
Verdict: AVOID
Clinical progress is overshadowed by a critical cash runway deficit and looming dilution risk required to fund Phase III completion.
Investment score: 38/100
Analysis as of
Is Prokidney Corp stock worth reviewing? The TradeMates thesis
The TradeMates model views PROK as a high-risk speculative play with deteriorating financial health due to a cash runway that likely ends in late 2026. Despite analyst optimism, the combination of negative equity and massive valuation premiums versus peers makes the risk-reward profile unfavorable for standard equity portfolios.
7-factor investment score
- Valuation: 25/100 (weight 20%)
- Financial Health: 20/100 (weight 15%)
- Technical Momentum: 45/100 (weight 15%)
- Earnings Quality: 55/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 60/100 (weight 10%)
- Risk-Adjusted Return: 35/100 (weight 15%)
Prokidney Corp opportunities and risks
What speaks for PROK
- Phase III REACT Success
What speaks against PROK
- Near-Term Liquidity Crisis / Dilution
Peers and competitors
- CADL
- ALT
- PRME
- AVTX
- KYTX
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| PROK | n/a | 603.0x | n/a | -218.8% | -7725.2% | -25.1% |
| CADL | n/a | 0.0x | n/a | 0.0% | 0.0% | -8.5% |
| ALT | n/a | 6651.6x | n/a | -36387.8% | -214861.0% | -24.9% |
| PRME | n/a | 143.7x | n/a | -1082.7% | -4917.6% | -27.4% |
| AVTX | n/a | 4129.1x | n/a | 72.9% | -132642.4% | -21.1% |
| KYTX | n/a | 0.0x | n/a | 0.0% | 0.0% | -37.7% |
| Peer median | n/a | 143.7x | n/a | 0.0% | -4917.6% | -24.9% |
Frequently asked questions about Prokidney Corp (PROK)
Is PROK stock a good investment?
The TradeMates model rates Prokidney Corp as AVOID with an investment score of 38/100. The TradeMates model views PROK as a high-risk speculative play with deteriorating financial health due to a cash runway that likely ends in late 2026. Despite analyst optimism, the combination of negative equity and massive valuation premiums versus peers makes the risk-reward profile unfavorable for standard equity portfolios. This is algorithmic model output, not personal investment advice.
Is PROK stock a buy?
The TradeMates model verdict for PROK is AVOID with an investment score of 38/100. Treat this as a model signal to review, not a personal buy recommendation.